Quest Diagnostics 미래 성장

Future 기준 확인 1/6

Quest Diagnostics (는) 각각 연간 11.7% 및 5% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 11.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 15.5% 로 예상됩니다.

주요 정보

11.7%

수익 성장률

11.1%

EPS 성장률

Healthcare 수익 성장	20.8%
매출 성장률	5.0%
향후 자기자본 수익률	15.5%
애널리스트 커버리지	Good
마지막 업데이트	17 Dec 2024

최근 미래 성장 업데이트

Earnings Update: Quest Diagnostics Incorporated (NYSE:DGX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Oct 25

Results: Quest Diagnostics Incorporated Beat Earnings Expectations And Analysts Now Have New Forecasts

Apr 26

Recent updates

Earnings Update: Quest Diagnostics Incorporated (NYSE:DGX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Oct 25

Quest Diagnostics: Organic Growth Leads To Q3 Earnings Beat

Oct 24

Why Investors Shouldn't Be Surprised By Quest Diagnostics Incorporated's (NYSE:DGX) P/E

Oct 23

Quest Diagnostics: The Better Half Of An Emerging Healthcare Duopoly

Oct 15

These 4 Measures Indicate That Quest Diagnostics (NYSE:DGX) Is Using Debt Reasonably Well

Aug 30

Should You Think About Buying Quest Diagnostics Incorporated (NYSE:DGX) Now?

Aug 12

Quest Diagnostics: Beat Down After Beating Q2 Estimates

Jul 28

The Price Is Right For Quest Diagnostics Incorporated (NYSE:DGX)

Jul 12

Quest Diagnostics: On A Quest For Growth

Jul 12

Quest Diagnostics (NYSE:DGX) Hasn't Managed To Accelerate Its Returns

May 14

Quest Diagnostics: Let's Keep Waiting

May 08

Results: Quest Diagnostics Incorporated Beat Earnings Expectations And Analysts Now Have New Forecasts

Apr 26

We Think Quest Diagnostics (NYSE:DGX) Can Stay On Top Of Its Debt

Apr 23

Unpleasant Surprises Could Be In Store For Quest Diagnostics Incorporated's (NYSE:DGX) Shares

Apr 02

Quest Diagnostics (NYSE:DGX) Is Paying Out A Larger Dividend Than Last Year

Mar 15

Quest Diagnostics (NYSE:DGX) Has Announced That It Will Be Increasing Its Dividend To $0.75

Feb 06

Quest Diagnostics: Post-COVID Normalization Pretty Much Done

Feb 05

Quest Diagnostics (NYSE:DGX) Seems To Use Debt Quite Sensibly

Jan 11

Why We're Not Concerned About Quest Diagnostics Incorporated's (NYSE:DGX) Share Price

Dec 24

Quest Diagnostics: Market Overreaction Creates Investment Opportunity

Dec 08

Quest Diagnostics: Moving Past Covid

Oct 25

Quest Diagnostics: Q2 Earnings Reveal Promising Growth Trends Despite Dwindling COVID Testing Revenues

Aug 15

Quest Diagnostics: Healthier Diagnosis

May 30

수익 및 매출 성장 예측

NYSE:DGX - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	11,050	1,092	1,308	1,700	14
12/31/2025	10,664	1,004	1,162	1,531	16
12/31/2024	9,833	910	931	1,286	14
9/30/2024	9,539	838	1,023	1,397	N/A
6/30/2024	9,346	836	875	1,248	N/A
3/31/2024	9,287	842	947	1,332	N/A
12/31/2023	9,252	850	864	1,272	N/A
9/30/2023	9,297	759	596	1,079	N/A
6/30/2023	9,488	790	878	1,374	N/A
3/31/2023	9,603	789	864	1,332	N/A
12/31/2022	9,883	942	1,314	1,718	N/A
9/30/2022	10,294	1,230	1,464	1,865	N/A
6/30/2022	10,582	1,479	1,552	1,924	N/A
3/31/2022	10,679	1,874	1,602	1,982	N/A
12/31/2021	10,788	1,988	1,830	2,233	N/A
9/30/2021	11,046	2,175	1,872	2,293	N/A
6/30/2021	11,058	2,238	2,171	2,594	N/A
3/31/2021	10,335	1,794	2,068	2,489	N/A
12/31/2020	9,437	1,425	1,587	2,005	N/A
9/30/2020	8,361	1,101	1,384	1,812	N/A
6/30/2020	7,531	749	816	1,249	N/A
3/31/2020	7,657	771	779	1,215	N/A
12/31/2019	7,726	835	843	1,243	N/A
9/30/2019	7,639	709	811	1,190	N/A
6/30/2019	7,572	707	929	1,293	N/A
3/31/2019	7,538	720	938	1,295	N/A
12/31/2018	7,531	733	817	1,200	N/A
9/30/2018	7,557	860	914	1,228	N/A
6/30/2018	7,524	808	N/A	1,188	N/A
3/31/2018	7,469	782	N/A	1,159	N/A
12/31/2017	7,402	769	N/A	1,175	N/A
9/30/2017	7,398	671	N/A	1,156	N/A
6/30/2017	7,427	701	N/A	1,095	N/A
3/31/2017	7,469	702	N/A	1,112	N/A
12/31/2016	7,214	642	N/A	1,116	N/A
9/30/2016	7,503	675	N/A	1,037	N/A
6/30/2016	7,498	825	N/A	948	N/A
3/31/2016	7,517	748	N/A	922	N/A
12/31/2015	7,493	706	N/A	821	N/A
9/30/2015	7,527	703	N/A	852	N/A
6/30/2015	7,551	491	N/A	911	N/A
3/31/2015	7,528	507	N/A	906	N/A
12/31/2014	7,435	549	N/A	944	N/A
9/30/2014	7,308	506	N/A	845	N/A
6/30/2014	7,192	780	N/A	761	N/A
3/31/2014	7,105	799	N/A	689	N/A
12/31/2013	7,146	811	N/A	652	N/A

애널리스트 미래 성장 예측

수입 대 저축률: DGX 의 연간 예상 수익 증가율( 11.7% )이 saving rate( 2.6% 보다 높습니다. ).

수익 vs 시장: DGX 의 연간 수익( 11.7% ) US 시장( 15.2% 보다 느리게 성장할 것으로 예상됩니다. 15.2% 연간).

고성장 수익: DGX 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: DGX 의 수익(연간 5% ) US 시장( 9.1% 보다 느리게 성장할 것으로 예상됩니다. 9.1% 연간).

고성장 수익: DGX 의 수익(연간 5% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: DGX 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 15.5 %).

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/22 22:25
장 마감 주가	2024/12/20 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Quest Diagnostics Incorporated 46 애널리스트 중 16 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Jasper Hellweg	Argus Research Company
Brian Kemp Dolliver	Avondale Partners
Eric Coldwell	Baird

Quest Diagnostics 미래 성장

Future 기준 확인 1/6

주요 정보

최근 미래 성장 업데이트

Earnings Update: Quest Diagnostics Incorporated (NYSE:DGX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Quest Diagnostics Incorporated Updates Earnings Outlook for 2024

Quest Diagnostics Incorporated Updates Earnings Outlook for 2024

Quest Diagnostics Incorporated Updates Earnings Guidance for the Full Year of 2024

Results: Quest Diagnostics Incorporated Beat Earnings Expectations And Analysts Now Have New Forecasts

Quest Diagnostics Incorporated Updates Earnings Guidance for the Full Year of 2024

Recent updates

Is Quest Diagnostics (NYSE:DGX) A Risky Investment?

Quest Diagnostics Launches Health Coaching on Questhealth.com to Help Individuals Take Control of Their Health

Senior VP & General Counsel notifies of intention to sell stock

Is Now The Time To Look At Buying Quest Diagnostics Incorporated (NYSE:DGX)?

Third quarter dividend of US$0.75 announced

Quest Diagnostics Declares Quarterly Cash Dividend, Payable on January 29, 2025

Investors Met With Slowing Returns on Capital At Quest Diagnostics (NYSE:DGX)

Senior VP exercised options and sold US$1.6m worth of stock

Earnings Update: Quest Diagnostics Incorporated (NYSE:DGX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Quest Diagnostics: Organic Growth Leads To Q3 Earnings Beat

Quest Diagnostics Incorporated Updates Earnings Outlook for 2024

Why Investors Shouldn't Be Surprised By Quest Diagnostics Incorporated's (NYSE:DGX) P/E

Third quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Quest Diagnostics Incorporated Updates Earnings Outlook for 2024

Quest Diagnostics Introduces Specimen Self-Collection for Common Genital Tract Infection Testing at Nationwide Network of Patient Service Centers

Quest Diagnostics: The Better Half Of An Emerging Healthcare Duopoly

Quest Diagnostics Incorporated (NYSE:DGX) completed the acquisition of Select Assets of Outreach Laboratory Services Business of University Hospitals from University Hospitals Health System, Inc.

Upcoming dividend of US$0.75 per share

Quest Diagnostics Incorporated to Report Q3, 2024 Results on Oct 22, 2024

Quest Diagnostics Incorporated (NYSE:DGX) completed the acquisition of Select laboratory assets of Allina Health System, Inc.

Senior VP & General Counsel notifies of intention to sell stock

These 4 Measures Indicate That Quest Diagnostics (NYSE:DGX) Is Using Debt Reasonably Well

Second quarter dividend of US$0.75 announced

Quest Diagnostics Incorporated Introduces 13 New Blood Tests to Identify Micronutrient Deficiencies

Should You Think About Buying Quest Diagnostics Incorporated (NYSE:DGX) Now?

Quest Diagnostics: Beat Down After Beating Q2 Estimates

Second quarter 2024 earnings: EPS misses analyst expectations

Quest Diagnostics Incorporated Updates Earnings Guidance for the Full Year of 2024

The Price Is Right For Quest Diagnostics Incorporated (NYSE:DGX)

Quest Diagnostics: On A Quest For Growth

Quest Diagnostics Incorporated to Report Q2, 2024 Results on Jul 23, 2024

Quest Diagnostics Incorporated (NYSE:DGX) completed the acquisition of Select assets of PathAI Diagnostics.

First quarter dividend of US$0.75 announced

Quest Diagnostics Elects Robert B. Carte to Board of Directors

Quest Diagnostics Incorporated Declares Quarterly Cash Dividend, Payable on July 22, 2024

Quest Diagnostics (NYSE:DGX) Hasn't Managed To Accelerate Its Returns

Quest Diagnostics: Let's Keep Waiting

Quest Diagnostics Appoints Murali Balakumar as Senior Vice President and Chief Information and Digital Officer

Results: Quest Diagnostics Incorporated Beat Earnings Expectations And Analysts Now Have New Forecasts

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Quest Diagnostics Incorporated Updates Earnings Guidance for the Full Year of 2024

We Think Quest Diagnostics (NYSE:DGX) Can Stay On Top Of Its Debt

Quest Diagnostics Incorporated, Annual General Meeting, May 16, 2024

Unpleasant Surprises Could Be In Store For Quest Diagnostics Incorporated's (NYSE:DGX) Shares

Upcoming dividend of US$0.75 per share

Quest Diagnostics Incorporated to Report Q1, 2024 Results on Apr 23, 2024

Quest Diagnostics (NYSE:DGX) Is Paying Out A Larger Dividend Than Last Year

Insider notifies of intention to sell stock

Quest Diagnostics Incorporated Announces the Launch of MelaNodal Predict

Quest Diagnostics Incorporated Announces the Availability of the First Consumer-Initiated, Physician-Ordered Blood-Draw Test for PFAS Chemicals

Quest Diagnostics (NYSE:DGX) Has Announced That It Will Be Increasing Its Dividend To $0.75

Quest Diagnostics: Post-COVID Normalization Pretty Much Done

Dividend of US$0.75 announced

Full year 2023 earnings: EPS misses analyst expectations

Quest Diagnostics Incorporated Provides Earnings Guidance for the Full Year of 2024

Quest Diagnostics Incorporated to Report Q4, 2023 Results on Feb 01, 2024

Quest Diagnostics (NYSE:DGX) Seems To Use Debt Quite Sensibly

Upcoming dividend of US$0.71 per share at 2.0% yield

Why We're Not Concerned About Quest Diagnostics Incorporated's (NYSE:DGX) Share Price

Quest Diagnostics, Inc. Appoints Yuri A. Fesko, M.D. as Senior Vice President and Chief Medical Officer

Quest Diagnostics Launches New 88-Compound Novel Psychoactive Substance Test Panel

Quest Diagnostics: Market Overreaction Creates Investment Opportunity

Quest Diagnostics Declares Quarterly Cash Dividend, Payable on January 31, 2024

Quest Diagnostics Launches Mobile Phlebotomy Service, Enabling Convenient At-Home Specimen Collection in the United States

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Quest Diagnostics Incorporated Updates Earnings Guidance for the Full Year 2023

Quest Diagnostics: Moving Past Covid

Quest Diagnostics Incorporated to Report Q3, 2023 Results on Oct 24, 2023

Upcoming dividend of US$0.71 per share at 2.3% yield